Preliminary clinical data, including responses observed with revumenib and ziftomenib in early-phase trials (e.g., AUGMENT-101), support the extension of this therapeutic approach beyond KMT2A-rearranged and NPM1-mutated AML. Here, NPM1 is linked to acute myeloid leukemia.